New Data Regarding Fibroid Treatment
Halt Medical, Inc. has announced that two research studies regarding the Acessa System will be presented this week at the 25th Annual Meeting of the European Society for Gynaecological Endoscopy in Brussels, Belgium.
BRENTWOOD, Calif., Oct. 3, 2016 /PRNewswire/ -- Halt Medical, Inc. has announced that two research studies regarding the Acessa System will be presented this week at the 25th Annual Meeting of the European Society for Gynaecological Endoscopy in Brussels, Belgium. Dr. Bernhard Kramer of the University of Tubingen will present the three-year follow-up results from the LUSTOR Study and Dr. John Thiel, Clinical Professor at the University of Saskatchewan, will discuss how a group of 10 surgeons participating in the TRUST Study gained proficiency using the first generation Acessa System in just two to five procedures.
Fibroids are benign, muscular tumors in a woman's uterus that can cause heavy bleeding, painful periods, pressure, and distention of the abdomen. At least 70 percent of women in the U.S. will develop fibroids by the age of 50, and the prevalence is higher among African American women. The Acessa Procedure is performed by laparoscopic gynecologists; a minimally invasive, uterus sparing alternative to hysterectomy and myomectomy. The surgeon uses ultrasound guidance and a small scope to locate the patient's fibroids, then treats each fibroid with radiofrequency energy while leaving the surrounding tissue unharmed. Treated patients typically return home the same day, experience a rapid recovery, and return to work or normal activities within five days. In patients requiring pain relief after surgery, only over-the-counter pain relievers are typically required. The majority of patients experience relief from fibroid symptoms shortly after undergoing the procedure, with heavy bleeding noticeably improved in three to six months.
Dr. John Thiel, Academic Head of OB/GYN at the University of Saskatchewan stated, "I have used the Acessa System to treat dozens of women with symptomatic fibroids and have been impressed with the rapid recovery, minimal post-operative pain, and quick resolution of symptoms expressed by my patients." Dr. Thiel will share the post-operative outcomes and surgeons' feedback after the treatment of 40 women with symptomatic fibroids.
The NIH has determined that direct health care costs for the surgical treatment of fibroids is more than $2.1 billion annually. They state, "Fibroids are an important public health concern, both because of the large number of women affected by them and the large number of hysterectomies undertaken to treat the symptoms they cause."
1. www.womenshealth.gov
2. Baird DD et al. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol 2003; 188 (1):100-107.
3. National Institutes of Health fact sheet: http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=50
Halt Medical is focused on establishing a new standard of care for women with symptomatic uterine fibroids. The procedure is cleared by the FDA and has CE mark for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Company is located in Brentwood, CA. For information about the Acessa System, please visit http://www.acessaprocedure.com.
SOURCE: Halt Medical, Inc.
WEBSITE: http://www.acessaprocedure.com
CONTACT: For investor relations, please contact: Jeremy McFadden, CFO, [email protected], 925-348-9911
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.
SOURCE Halt Medical, Inc.
Share this article